Muir-Torre syndrome: A case report and review of the literature

Cutis

Volumn 75, Issue 3, 2005, Pages 149-155

  Pettey, Adam A ^a   Walsh, John S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ISOTRETINOIN;

ADULT; CANCER RISK; CASE REPORT; COLORECTAL CANCER; FAMILY HISTORY; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL LITERATURE; MISMATCH REPAIR; MUIR TORRE SYNDROME; PHENOTYPE; PROTEIN DEFECT; REVIEW; SCREENING; SEBACEOUS CARCINOMA; SKIN TUMOR;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; HUMANS; MALE; MIDDLE AGED; SEBACEOUS GLAND NEOPLASMS; SYNDROME;

EID: 17144427311     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med. 1991;90:606-613.
2. Muir EG, Bell AJY, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967;54:191-195.
3. Torre D. Society transactions: New York Dermatological Society, Oct 24, 1967 (multiple sebaceous tumors). Arch Dermatol. 1968;98:549-551.
4. Esche C, Kruse R, Lamberti C, et al. Muir-Torre syndrome: clinical and molecular genetic analysis. Br J Dermatol. 1997;136:913-917.
5. Fahmy A, Burgdorf WH, Schosser RH, et al. Muir-Torre syndrome: report of a case and reevaluation of the dermatopathologic features. Cancer. 1982;49:1898-1903.
6. Akhtar S, Oza K, Khan S, et al. Muir-Torre syndrome: case report of a patient with concurrent jejunal and ureteral cancer and a review of literature. J Am Acad Dermatol. 1999;41:681-686.
7. Cohen PR, Kohn SR, Davis DA, et al. Muir-Torre syndrome. Dermatol Clin. 1995;13:79-89.
8. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33:90-104.
9. Abbott JJ, Hernandez-Rios P, Amirkhan RH, et al. Cystic sebaceous neoplasms in Muir-Torre syndrome. Arch Pathol Lab Med. 2003;127:614-617.
10. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer. 1974;33:82-102.
11. Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors, a sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999;21:426-431.
12. Ansai S, Hashimoto H, Aoki T, et al. A histochemical and immunohistochemical study of extra-ocular sebaceous carcinoma. Histopathology. 1993;22:127-133.
13. Rutten A, Burgdorf W, Hugel H, et al. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study. Am J Dermatopathol. 1999;21:405-413.
14. Finan MC, Connolly SM. Sebaceous gland tumors and systemic disease: a clinicopathologic analysis. Medicine (Baltimore). 1984;63:232-242.
15. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med. 2004;10:136-141.
16. Zouboulis CC, Boschnakow A. Chronological ageing and photoageing of the human sebaceous gland. Clin Exp Dermatol. 2001;26:600-607.
17. Callahan EF, Appert DL, Roenigk RK, et al. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004;30:1164-1168.
18. Graefe T, Wollina U, Schulz H, et al. Muir-Torre syndrome - treatment with isotretinoin and interferon alpha-2a can prevent tumour development. Dermatology. 2000;200:331-333.
19. Kruse R, Rutten A, Lamberti C, et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutation similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam Criteria. Am J Hum Genet. 1998;63:63-70.
20. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetics and clinical implications. Ann Intern Med. 2003;138:560-570.
21. Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers [review]. Mol Cancer. 2003;2:41.
22. Kruse R, Rutten A, Hosseiny-Malayeri HR, et al. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation. J Invest Dermatol. 2001;116:463-465.
23. Machin P, Catasus L, Pons C, et al. Microsatellite instability and immunostaining for MSH2 and MLH1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. J Cutan Pathol. 2002;29:415-420.
24. Entius MM, Keller JJ, Drillenburg P, et al. Microsatellite instability and expression of hMLH1 and hMSH2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res. 2000;6:1784-1789.
25. Kariola R, Raevaara TE, Lonnqvist KE, et al. Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome. Hum Mol Genet. 2002;11:1303-1310.
26. Kruse R, Rutten A, Schweiger N, et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol. 2003;120:858-864.
27. Popnikolov N, Gatalica Z, Colome-Grimmer MI, et al. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol. 2003;30:178-184.
28. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol. 2002;26:338-343.
29. Curry ML, Eng W, Lund K, et al. Muir-Torre syndrome: role of the dermatopathologist in diagnosis. Am J Dermatopathol. 2004;26:217-221.